Privately-owned Austrian biotech Themis Bioscience announced today a research collaboration and exclusive license agreement with Merck & Co (NYSE: MRK), known as MSD outside the USA and Canada, for the discovery and development of undisclosed vaccine candidates using Themis’ measles virus vector-based platform, marking the Vienna-based firm’s first deal with a pharma major.
“Given the versatility of our immune-modulation platform and our proven ability to rapidly generate product candidates across a broad range of infectious disease and cancer indications, our partnership with MSD, a global leader in vaccine development, validates the potential of our measles virus-based technology,” said Dr Erich Tauber, chief executive of Themis Bioscience.”
Deal potentially worth $200 million to Themis
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze